TD Cowen analyst Phil Nadeau reiterated a Buy rating and $130.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).

The analyst commented: "CEO Meeker and CFO Smith's Strategy To Build Rhythm; We speak with CEO David Meeker and CFO Hunter Smith from TD Cowen's 46th Annual Health Care conference about the strategy for growing RYTM into a leading orphan obesity company. RYTM is beginning its most significant launch yet and management is confident Imcivree will set a new standard of care in HO. Management discusses add'l oppy's and lifecycle management. RYTM is a top smid biotech pick."

For an analyst ratings summary and ratings history on Rhythm Pharmaceuticals click here. For more ratings news on Rhythm Pharmaceuticals click here.

Shares of Rhythm Pharmaceuticals closed at $84.65 yesterday.